Britta Heinze

Wuerzburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Continuous flow-through steady state system for in vitro characterization of CYP11B2 inhibitors-Impact on enzyme kinetics of steroidogenesis.

Continuous flow-through steady state system for in vitro characterization of CYP11B2 inhibitors-Impact on enzyme kinetics of steroidogenesis.

Journal: The Journal of steroid biochemistry and molecular biology

Published: November 11, 2024

Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen-Directed PET/CT.

Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen-Directed PET/CT.

Journal: Clinical nuclear medicine

Published: February 13, 2024

Fluorinated aldosterone synthase (CYP11B2)-inhibitors for differential diagnosis between bilateral and unilateral conditions of primary aldosteronism.

Fluorinated aldosterone synthase (CYP11B2)-inhibitors for differential diagnosis between bilateral and unilateral conditions of primary aldosteronism.

Journal: Bioorganic & medicinal chemistry letters

Published: August 14, 2023

Multiple TP53 p.R337H haplotypes and implications for tumor susceptibility.

Multiple TP53 p.R337H haplotypes and implications for tumor susceptibility.

Journal: HGG advances

Published: July 11, 2023

Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.

Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.

Journal: The Journal of clinical endocrinology and metabolism

Published: September 24, 2021

Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma.

Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma.

Journal: Cancers

Published: August 02, 2021

Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience.

Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience.

Journal: European journal of nuclear medicine and molecular imaging

Published: December 17, 2020

Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma.

Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma.

Journal: Frontiers in endocrinology

Published: August 22, 2020

Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma.

Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: July 15, 2017

Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.

Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.

Journal: Clinical nuclear medicine

Published: November 08, 2016

Prevalence of Malignancies in Patients With Primary Aldosteronism.

Prevalence of Malignancies in Patients With Primary Aldosteronism.

Journal: The Journal of clinical endocrinology and metabolism

Published: February 05, 2016

Eya4 Induces Hypertrophy via Regulation of p27kip1.

Eya4 Induces Hypertrophy via Regulation of p27kip1.

Journal: Circulation. Cardiovascular genetics

Published: May 05, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026